The shares are up 4.1% before the open, after the news came Monday following the close of trading. Peter Loftus of Dow Jones Newswires reports:
A new clinical study showed an experimental Bristol-Myers Squibb Co. (BMY) drug-awaiting a U.S. regulatory decision this week-improved overall survival in previously untreated patients with a deadly form of skin cancer, the company said Monday.
The study's results could help widen the potential patient population for the drug, ipilimumab, bolstering some analysts' estimates that annual sales could exceed $1 billion. Bristol proposes to sell the drug under the brand name Yervoy.
For more, check out coverage over on WSJ.com's Health Blog.view original article